Literature DB >> 19464370

Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

Liliana Menalled1, Bassem F El-Khodor, Monica Patry, Mayte Suárez-Fariñas, Samantha J Orenstein, Benjamin Zahasky, Christina Leahy, Vanessa Wheeler, X William Yang, Marcy MacDonald, A Jennifer Morton, Gill Bates, Janet Leeds, Larry Park, David Howland, Ethan Signer, Allan Tobin, Daniela Brunner.   

Abstract

Huntington's disease (HD) is one of the few neurodegenerative diseases with a known genetic cause, knowledge that has enabled the creation of animal models using genetic manipulations that aim to recapitulate HD pathology. The study of behavioral and neuropathological phenotypes of these HD models, however, has been plagued by inconsistent results across laboratories stemming from the lack of standardized husbandry and testing conditions, in addition to the intrinsic differences between the models. We have compared different HD models using standardized conditions to identify the most robust phenotypic differences, best suited for preclinical therapeutic efficacy studies. With a battery of tests of sensory-motor function, such as the open field and prepulse inhibition tests, we replicate previous results showing a strong and progressive behavioral deficit in the R6/2 line with an average of 129 CAG repeats in a mixed CBA/J and C57BL/6J background. We present the first behavioral characterization of a new model, an R6/2 line with an average of 248 CAG repeats in a pure C57BL/6J background, which also showed a progressive and robust phenotype. The BACHD in a FVB/N background showed robust and progressive behavioral phenotype, while the YAC128 full-length model on either an FVB/N or a C57BL/6J background generally showed milder deficits. Finally, the Hdh(Q111) knock-in mouse on a CD1 background showed very mild deficits. This first extensive standardized cross-characterization of several HD animal models under standardized conditions highlights several behavioral outcomes, such as hypoactivity, amenable to standardized preclinical therapeutic drug screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464370      PMCID: PMC2728344          DOI: 10.1016/j.nbd.2009.05.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  42 in total

Review 1.  Mouse models of Huntington's disease.

Authors:  Liliana B Menalled; Marie-Françoise Chesselet
Journal:  Trends Pharmacol Sci       Date:  2002-01       Impact factor: 14.819

2.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

3.  Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.

Authors:  A Jennifer Morton; Nigel I Wood; Michael H Hastings; Carrie Hurelbrink; Roger A Barker; Elizabeth S Maywood
Journal:  J Neurosci       Date:  2005-01-05       Impact factor: 6.167

4.  The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.

Authors:  Ben Woodman; Rachel Butler; Christian Landles; Michelle K Lupton; Jamie Tse; Emma Hockly; Hilary Moffitt; Kirupa Sathasivam; Gillian P Bates
Journal:  Brain Res Bull       Date:  2006-12-05       Impact factor: 4.077

5.  Inbred strain differences in prepulse inhibition of the mouse startle response.

Authors:  R Paylor; J N Crawley
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

6.  Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Authors:  Liliana B Menalled; Jessica D Sison; Ying Wu; Melisa Olivieri; Xiao-Jiang Li; He Li; Scott Zeitlin; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.

Authors:  A Jennifer Morton; Dervila Glynn; Wendy Leavens; Zhiguang Zheng; Richard L M Faull; Jeremy N Skepper; James M Wight
Journal:  Neurobiol Dis       Date:  2008-12-11       Impact factor: 5.996

8.  Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.

Authors:  Tara L Spires; Helen E Grote; Neelash K Varshney; Patricia M Cordery; Anton van Dellen; Colin Blakemore; Anthony J Hannan
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

9.  Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent.

Authors:  H Telenius; H P Kremer; J Theilmann; S E Andrew; E Almqvist; M Anvret; C Greenberg; J Greenberg; G Lucotte; F Squitieri
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

10.  Standardization and statistical approaches to therapeutic trials in the R6/2 mouse.

Authors:  Emma Hockly; Benjamin Woodman; Amarbirpal Mahal; Cathryn M Lewis; Gillian Bates
Journal:  Brain Res Bull       Date:  2003-09-30       Impact factor: 4.077

View more
  145 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

3.  Genetic background modulates behavioral impairments in R6/2 mice and suggests a role for dominant genetic modifiers in Huntington’s disease pathogenesis.

Authors:  Randi-Michelle Cowin; Nghiem Bui; Deanna Graham; Jennie R Green; Lisa A Yuva-Paylor; Andreas Weiss; Richard Paylor
Journal:  Mamm Genome       Date:  2012-06       Impact factor: 2.957

Review 4.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 5.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

6.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

7.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

8.  Early Detection of Apathetic Phenotypes in Huntington's Disease Knock-in Mice Using Open Source Tools.

Authors:  Shawn Minnig; Robert M Bragg; Hardeep S Tiwana; Wes T Solem; William S Hovander; Eva-Mari S Vik; Madeline Hamilton; Samuel R W Legg; Dominic D Shuttleworth; Sydney R Coffey; Jeffrey P Cantle; Jeffrey B Carroll
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

9.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012

10.  A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease.

Authors:  Marianne R Smith; Adeela Syed; Tamas Lukacsovich; Judy Purcell; Brett A Barbaro; Shane A Worthge; Stephen R Wei; Giuseppe Pollio; Letizia Magnoni; Carla Scali; Luisa Massai; Davide Franceschini; Michela Camarri; Marco Gianfriddo; Enrica Diodato; Russell Thomas; Ozgun Gokce; S J Tabrizi; Andrea Caricasole; Bernard Landwehrmeyer; Liliana Menalled; Carol Murphy; Sylvie Ramboz; Ruth Luthi-Carter; Goran Westerberg; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-01-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.